These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 645439)

  • 1. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
    Ringborg U; Lewensohn R
    Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melphalan in multiple myeloma.
    Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF
    Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).
    Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF
    Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.
    Rivers SL; Patno ME
    JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple myeloma--intermittent combination chemotherapy compared to continuous therapy.
    George RP; Poth JL; Gordon D; Schrier SL
    Cancer; 1972 Jun; 29(6):1665-70. PubMed ID: 4113171
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
    Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkeran and multiple myeloma.
    Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
    [No Abstract]   [Full Text] [Related]  

  • 9. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Hohaus S; Haas R
    Br J Haematol; 1997 Sep; 98(3):736-44. PubMed ID: 9332333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 14. Alkylating agents as leukemogens in multiple myeloma.
    Karchmer RK; Amare M; Larsen WE; Mallouk AG; Caldwell GG
    Cancer; 1974 Apr; 33(4):1103-7. PubMed ID: 4522494
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acute myelogenous leukemia in myelomatosis].
    Tidsskr Nor Laegeforen; 1977 Feb; 97(4):175-7. PubMed ID: 265102
    [No Abstract]   [Full Text] [Related]  

  • 16. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
    Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan].
    Morlock G; Bataille R; Sany J; Serre H
    Sem Hop; 1977 Apr 9-16; 53(14-15):853-6. PubMed ID: 194338
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
    Harley JB; Pajak TF; McIntyre OR; Kochwa S; Cooper MR; Coleman M; Cuttner J
    Blood; 1979 Jul; 54(1):13-22. PubMed ID: 444661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.